Literature DB >> 28819889

Visualization of 57Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging.

Makoto Kihara1, Yukari Matsuo-Tezuka2, Mariko Noguchi-Sasaki2, Keigo Yorozu2, Mitsue Kurasawa2, Yasushi Shimonaka2, Michinori Hirata2.   

Abstract

Epoetin beta pegol (continuous erythropoiesis receptor activator; C.E.R.A.), or methoxy-polyethylene glycol-modified epoetin beta, is a long-acting erythropoiesis stimulating agent (ESA) that effectively maintains hemoglobin levels. It promotes proliferation of erythroid progenitor cells in hematopoietic organs and leads to increased reticulocyte and hemoglobin levels. However, the detailed erythropoietic effects of various ESAs on their target organs have yet to be clarified, and new approaches are needed to analyze tissue iron localization with structural information. Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) techniques are widely used in basic pharmaceutical research. High-resolution Fourier transform ion cyclotron resonance (FTICR) mass spectrometry (MS) imaging enables the spatial mapping and identification of biomolecules. In this study, mice administered with C.E.R.A. were fed a diet containing the stable iron isotope 57Fe. The 57Fe-heme+ isotopic fine structure peak (m/z 617.1772) was separated from the non-labeled heme+ isotopic peak (Δ0.0029) by FTICR-MS with a resolving power of more than 500,000. We optimized the platform to analyze the distribution of 57Fe-heme in the spleen using MALDI FTICR-MS imaging. The combination of the ultrahigh resolution power of FTICR-MS and a stable isotope labeling technique has the potential to be very effective in basic pharmaceutical research. Graphical Abstract ᅟ.

Entities:  

Keywords:  Epoetin beta pegol; Heme; High resolution; Isotopic fine structure; MALDI FTICR-MS imaging

Mesh:

Substances:

Year:  2017        PMID: 28819889      PMCID: PMC5645437          DOI: 10.1007/s13361-017-1768-y

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


Introduction

Erythropoietin is one of several hematopoietic factors and is essential for erythrocyte production. Erythropoiesis stimulating agents (ESAs), the active ingredients of whichare recombinant human erythropoietin or its modified form, have been widely used to treat patients with certain kinds of anemia, for example chronic kidney disease-associated anemia, in clinical practice [1]. In clinical settings, several ESA preparations are now available. C.E.R.A. is one of the long-acting ESAs. It differs from epoetin beta in having chemically attached methoxy-polyethylene glycol, which leads to extremely prolonged blood retention [2, 3]. Although there are differences among ESAs in terms of receptor binding affinity and blood retention, for example, the differences in erythropoietic effects in their target organs, such as bone marrow and spleen, have not yet been clarified. Natural iron is composed of four stable iron isotopes, 54Fe, 56Fe, 57Fe, and 58Fe, the relative isotopic abundances of which are 5.845%, 91.754%, 2.119%, and 0.282%, respectively [4, 5]. Instead of radioactive isotopes, 57Fe has been used as a tracer of exogenous iron in nutritional studies because of its low natural abundance, and inductively coupled plasma mass spectrometry (ICP-MS) for determination of stable iron isotopes ensures high sensitivity and provides quantitative data. 57Fe and ICP-MS have already been used to assess the process of iron absorption [5, 6]. Our recent study, combining 57Fe-labeling with ICP-MS technology, has provided quantitative analysis of dietary iron utilization for hemoglobin synthesis under stress erythropoiesis induced by C.E.R.A. administration in mice [7]. Based on the analysis of 57Fe-iron incorporation by ICP-MS, we were able to quantitatively observe not only the dynamics of dietary iron utilization for hemoglobin synthesis but also dietary iron distribution among tissues. Although this platform is very useful for analyzing the iron uptake, utilization, distribution and accumulation in tissues, and trafficking across tissues, another approach is necessary to analyze detailed tissue iron localization with structural information. Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS) is used to analyze extremely complex mixtures such as crude oil [8], proteome [9], and metabolome samples [10] because of its ultrahigh resolution (>1,000,000 full width at half-maximum at 7.0 T) and high mass accuracy (<1 ppm). Ultrahigh resolution mass spectrometry is also used to determine unknown compounds [11]. The ultrahigh resolution of FTICR-MS enable clear separation of stable isotopes such as 13C, 15N, 34S, and 18O, and the high mass accuracy allows candidates elemental compositions [12]. Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) techniques are widely used in basic research targeting biomolecules such as lipids, peptides, and proteins. The MALDI MSI technique has been used to image drug molecule and metabolite distribution in tissue sections [13-15]. Heme, as a cofactor of hemoglobin in red blood cells, is applicable for visualization target of the lumen of blood vessels in tissue [15]. MSI applications are increasingly providing more detailed visualization of administered drugs and localization of their metabolites in the tissues. In the case of MALDI-time-of-flight (TOF) MSI, the integration of rapid data acquisition, narrow laser focus (5–20 μm), and development of image analytical software established the capacity of producing high-resolution 3D images [16, 17]. These detailed 3D images were expected to have applications in biomarker discovery and in diagnosis [17]. However, the number of studies on potential applications of MALDI FTICR-MSI is still limited. Recently, Spraggins et al. reported the use of MALDI FTICR-MSI for protein analysis [18]. In their study, the ultrahigh resolution power and high mass accuracy (<5 ppm) of FTICR-MS enabled proteins to be identified with high levels of confidence [18]. The results indicated that FTICR-MS ultrahigh resolution power may be applicable to a MSI technique for biological molecules. The combination of FTICR-MS ultrahigh resolution power with a stable isotope labeling technique offers the potential of identifying the isotopic fine structure of specific biological molecules and visualize their localization in tissues. Here, we have demonstrated the application of MALDI FTICR-MSI combined with stable isotope labeling in pharmaceutical basic research. MALDI FTICR-MSI offers a solution to the problem of visualizing the fine isotopic structure of 57Fe-heme in mouse hematopoietic organs.

Experimental

Materials

C.E.R.A. used in this study was produced by Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Stable iron isotope 57Fe powder (95.95% purity) was purchased from Medical Isotopes (Pelham, NH, USA). All diets used in this study were purchased from Research Diets (New Brunswick, NJ, USA). This study used the following diets: 57Fe diet (diet mixed with 200 ppm of 57Fe instead of natural iron); and control diet (diet mixed with 200 ppm of natural iron). Male C57BL/6NCrl mice were purchased from Charles River Laboratories Japan (Hino, Japan). All animals were allowed to acclimatize and recover from shipping-related stress for 4 to 6 d prior to the study. Mice were housed under specific pathogen-free conditions with free access to food and water. All studies were approved by the Institutional Animal Care and Use Committee at Chugai Pharmaceutical Co., Ltd. C.E.R.A. was diluted to appropriate concentrations in phosphate buffer vehicle (PBS containing 0.02% polyoxyethylene sorbitan monooleate [Tween 80]). To evaluate the incorporation of labeled iron during C.E.R.A. treatment, mice fed the control diet were switched to the 57Fe diet immediately after being intravenously administered 10 μg/kg of C.E.R.A. or vehicle in a single injection. On day 5 after administration, mice were euthanized by exsanguination under anesthesia with isoflurane. Two mouse spleens from each group were harvested for MALDI FTICR-MSI.

Sample Preparation

The harvested spleens from each group (non-treatment [NT], vehicle, and C.E.R.A.) were fresh frozen with 2% carboxymethyl cellulose compounds. Frozen sections were cut at a thickness of 10 μm using a cryostat (CM3050S; Leica, Nussloch, Germany). The sections were coated with 30 mg/mL 2,5-dihydroxybenzoic acid (DHB; Wako Pure Chemical Industries, Ltd., Osaka, Japan) matrix solution (50% methanol, 0.1% TFA) using a TM-sprayer (HTX Technologies, Chapel Hill, NC, USA) without an ethanol wash. The matrix spraying conditions were velocity 1333 mm/min., flow rate 0.12 mL/min., temperature 110 °C, number of passes 4 (rotated 90° after pass #2), offsetting 1.5 mm, track spacing 3 mm, and sheath gas pressure 10 psi.

Mass Spectrometry: Data Acquisition

MALDI MS analyses were performed on a 7T solariX FTICR-MS (Bruker Daltonics, Billerica, MA, USA) in positive ion mode. Transients of 2 mega-words were collected for an experimental mass resolving power (m/Δm 50%) of more than 500,000 at m/z 616.1768. MS data were acquired with a single scan and step size of 50 μm with 98% data reduction mode between m/z 601.92 and 650.00 from 37,935 positions. The laser was operated at 1000 Hz with 150 laser shots at each position. The continuous accumulation of selected ions (CASI) was set as Q1 m/z 617.2 (isolation window: m/z 50.0) in FTMS control software (Bruker Daltonics). Lock mass calibration was performed at m/z 616.1768 in FTMS control software (Bruker Daltonics) [19]. MALDI MS images were generated using flexImaging software (Bruker Daltonics) with Δm/z = ± 0.001.

Results and Discussion

Detection of Heme b Signals

The heme b signals were efficiently observed from mouse spleens. A typical MALDI FTICR-MS spectrum is shown in Figure 1c. It was observed in the mass range m/z 614–621 from position #33,323 in non-treated mouse spleen. The observed ion isotopic pattern matched the theoretical isotopic distribution of heme b ions ([12C32-34 13C0-2 1H31-33 14N4 16O4 54-58Fe1]+) [20] that was calculated with DataAnalysis software (Bruker Daltonics). These heme b isotopic ions were detected efficiently as [M]+ by MALDI FTICR-MS from mouse spleen sections. In more broad mass range measurement [M + K]+ adduct ions were also observed but the intensity was weaker than that of [M]+ (data not shown). Therefore, we focused on heme b [M]+ for further analysis. It is well known that MALDI ionization is suppressed by salts and some types of lipid, so we compared the effects of using the 70% ethanol wash method or Carnoy’s fluid wash method [21] as a pretreatment, or no pretreatment, before using the matrix spray. We found that the heme b MALDI FTICR-MS intensity gradient patterns were quite similar with or without pretreatment, but that the heme b MALDI FTICR-MS intensity levels were reduced with 70% ethanol or Carnoy’s fluid wash (data not shown). The volatile buffer (50 mM ammonium formate, etc.) wash has the possibility of enhancing signal intensity [22]. But target molecules like proteins tend to be leaked. We could not find a washing condition suitable for heme b MSI (data not shown). In our experiments, the pretreatment wash before the matrix spray was therefore not effective for heme ionization in mouse spleens.
Figure 1

MALDI FTICR-MS spectra of heme b isotopic fine structure. (a) Expanded m/z window of heme b monoisotopic peak. These MS data were acquired at positions #33323/NT, #24722/vehicle, and #9963/C.E.R.A., shown in Figure 2e as white arrows. The MS data of heme b monoisotopic mass ([M]+), (m/z 616.1768 ± 0.001; pale blue line) was analyzed by flexImaging software and imaged as 56Fe-heme (Figure 2a). The 56Fe-heme peak resolving powers (RP) were 627,507 (#33323/NT), 649,350 (#24722/vehicle), and 639,973 (#9963/C.E.R.A.), respectively, at each position. The heme b monoisotopic mass m/z 616.1768 was set as the single point lock mass for MALDI FTICR-MSI. (b) Expanded m/z window of heme b first isotopic peak M + 1. The peaks, (i) 57Fe-heme: m/z 617.1772 [12C34 1H32 14N4 16O4 57Fe1]+, (ii) 56Fe-heme 13C: m/z 617.1801 [12C33 13C1 1H32 14N4 16O4 56 Fe1]+, and (iii) 56Fe-heme H33: m/z 617.1846 [12C34 1H33 14N4 16O4 56Fe1]+, were well separated with more than 500,000 RP. 57Fe-heme (m/z 617.1772 ± 0.001; pale orange line), and 56Fe-heme 13C (m/z 617.1801 ± 0.001; pale green line) were imaged as 57Fe-heme and 56Fe-heme 13C, respectively, (Figure 2b, c). (c) The heme b isotope distribution pattern in the mass range of m/z 614–621 at position #33323/NT. (d) Theoretical isotopic distribution patterns at RP approximately 617,000. Theoretical mass spectra C34H32N4O4 Fe1 (M + 1) and C34H33N4O4 Fe1 (M) are merged

MALDI FTICR-MS spectra of heme b isotopic fine structure. (a) Expanded m/z window of heme b monoisotopic peak. These MS data were acquired at positions #33323/NT, #24722/vehicle, and #9963/C.E.R.A., shown in Figure 2e as white arrows. The MS data of heme b monoisotopic mass ([M]+), (m/z 616.1768 ± 0.001; pale blue line) was analyzed by flexImaging software and imaged as 56Fe-heme (Figure 2a). The 56Fe-heme peak resolving powers (RP) were 627,507 (#33323/NT), 649,350 (#24722/vehicle), and 639,973 (#9963/C.E.R.A.), respectively, at each position. The heme b monoisotopic mass m/z 616.1768 was set as the single point lock mass for MALDI FTICR-MSI. (b) Expanded m/z window of heme b first isotopic peak M + 1. The peaks, (i) 57Fe-heme: m/z 617.1772 [12C34 1H32 14N4 16O4 57Fe1]+, (ii) 56Fe-heme 13C: m/z 617.1801 [12C33 13C1 1H32 14N4 16O4 56 Fe1]+, and (iii) 56Fe-heme H33: m/z 617.1846 [12C34 1H33 14N4 16O4 56Fe1]+, were well separated with more than 500,000 RP. 57Fe-heme (m/z 617.1772 ± 0.001; pale orange line), and 56Fe-heme 13C (m/z 617.1801 ± 0.001; pale green line) were imaged as 57Fe-heme and 56Fe-heme 13C, respectively, (Figure 2b, c). (c) The heme b isotope distribution pattern in the mass range of m/z 614–621 at position #33323/NT. (d) Theoretical isotopic distribution patterns at RP approximately 617,000. Theoretical mass spectra C34H32N4O4 Fe1 (M + 1) and C34H33N4O4 Fe1 (M) are merged
Figure 2

MALDI FTICR-MSI for 57Fe-heme and 56Fe-heme isotopes in mouse spleens. MSI data from (a) 56Fe-heme monoisotopic mass (56Fe-heme, m/z 616.1768 ± 0.001; pale blue line); (b) 57Fe-heme (m/z 617.1772 ± 0.001; pale orange line); and (c) 56Fe-heme 13C (m/z 617.1801 ± 0.001; pale green line) in C.E.R.A.-treated, vehicle-treated, and NT mouse spleens. In C.E.R.A.-treated mouse spleen, newly synthesized 57Fe-heme (m/z 617.1772) derived from the 57Fe-diet was clearly detectable, in contrast to vehicle-treated mouse spleen (b). (d) Merged MSI data from 56Fe-heme monoisotopic mass (a) and 57Fe-heme (b) (Δ1.0004). (e) Merged MSI data from 56Fe-heme 13C (c) and 57Fe-heme (b) (Δ0.0029). Scale bar indicates 2 mm (d), (e)

Detailed Analysis of Heme b First Isotopic Peak M + 1

In hematopoietic organs such as bone marrow and spleen, erythroid progenitors proliferate and differentiate into erythroblasts supported by erythropoietin [23]. Immature erythroblasts are induced to transcribe erythroid-specific 5-aminolevulinic acid synthase, the key enzyme of heme synthesis, which in turn triggers subsequent hemoglobin synthesis, leading to maturation of erythroblasts into erythrocytes [24]. As shown in our previous study [7], C.E.R.A. also stimulates hemoglobin synthesis partly using dietary iron, as assessed using an 57Fe-substituted diet and the ICP-MS platform. The heme b first isotopic peak M + 1 was resolved using FTICR-MS with more than 500,000 resolving power, and extended FTICR-MS profiles were shown from different positions (#33323/NT, #24722/vehicle, #9963/C.E.R.A., Figure 1b). The isotopic fine structure of heme b peak M + 1, including 57Fe-heme [12C34 1H32 14N4 16O4 57Fe1]+ at m/z 617.1772, 56Fe-heme 13C [12C33 13C1 1H32 14N4 16O4 56Fe1]+ at m/z 617.1801, and 56Fe-heme H33 [12C34 1H33 14N4 16O4 56Fe1]+ at m/z 617.1846, was observed. In the NT group, in which mice were fed the control diet, 56Fe-heme 13C and 56Fe-heme H33 peaks were detected but a 57Fe-heme peak was not identified within heme isotopic peak M + 1. However, in the vehicle and C.E.R.A.-treated groups, in which mice fed the control diet were switched to the 57Fe diet immediately after injection, 57Fe-heme peaks were detected in addition to 56Fe-heme 13C and 56Fe-heme H33 peaks (Figure 1b). Overall average spectra from 37,935 data positions were calculated with flexImaging software, and the 57Fe-heme peak (m/z 617.1772), 56Fe-heme 13C peak (m/z 617.1801), and 56Fe-heme H33 peak (m/z 617.1846) were well separated (data not shown).

MALDI FTICR-MSI of 57Fe-Heme and Non-Labeled Heme b Isotopes

In our experiment, splenomegaly (enlargement of the spleen) was observed in the C.E.R.A.-treated group (Figure 2). In rodents under stress erythropoiesis, extramedullary hematopoiesis is induced and splenomegaly is often observed because of the expansion of erythroid lineage cells. As previously reported [7], C.E.R.A. also induced extramedullary hematopoiesis accompanied by splenomegaly. Furthermore, the spleen, a component of the reticuloendothelium, is also known to act as an iron store, in which iron is stored in its ferritin-bound form. For these reasons, we selected spleen to visualize 57Fe-heme localization. MALDI FTICR-MSI for 57Fe-heme and 56Fe-heme isotopes in mouse spleens. MSI data from (a) 56Fe-heme monoisotopic mass (56Fe-heme, m/z 616.1768 ± 0.001; pale blue line); (b) 57Fe-heme (m/z 617.1772 ± 0.001; pale orange line); and (c) 56Fe-heme 13C (m/z 617.1801 ± 0.001; pale green line) in C.E.R.A.-treated, vehicle-treated, and NT mouse spleens. In C.E.R.A.-treated mouse spleen, newly synthesized 57Fe-heme (m/z 617.1772) derived from the 57Fe-diet was clearly detectable, in contrast to vehicle-treated mouse spleen (b). (d) Merged MSI data from 56Fe-heme monoisotopic mass (a) and 57Fe-heme (b) (Δ1.0004). (e) Merged MSI data from 56Fe-heme 13C (c) and 57Fe-heme (b) (Δ0.0029). Scale bar indicates 2 mm (d), (e) In FTICR-MSI to resolve isotopic fine structure peaks, precise mass calibration is critical at every data acquisition point. We have optimized a MALDI FTICR-MSI platform in which data acquisition of the heme b monoisotopic mass (56Fe-heme) m/z 616.1768 was set as the single point lock mass, and accurate m/z adjustment was performed through all data points [19]. FlexImaging software visualized the 57Fe-heme peak (m/z 617.1772 ± 0.001; red) and the 56Fe-heme 13C peak (m/z 617.1801 ± 0.001; green) based on their peak intensities and location information (Figure 2). The 57Fe-heme peak (m/z 617.1772 ± 0.001; red) was detected in the entire spleen area with signal intensity gradients in C.E.R.A.-treated mice, detected at very low levels in vehicle-treated mice, and was almost undetectable in NT mice (Figure 2b). The 56Fe-heme 13C peak (m/z 617.1801 ± 0.001; green) was detected in the entire spleen area with signal intensity gradients in C.E.R.A.-treated, vehicle-treated, and NT mice (Figure 2c). There was a Δ0.0029 difference between the 57Fe-heme peak and the 56Fe-heme 13C peak (m/z 617.1801). The heme b monoisotopic mass peak (56Fe-heme, m/z 616.1768 ± 0.001; pale blue) was visualized and detected in the entire spleen area in C.E.R.A.-treated, vehicle-treated, and NT mice (Figure 2a). The MSI results for the heme b monoisotopic mass peak (56Fe-heme) showed similarity to the signal intensity gradient pattern of the 56Fe-heme 13C peak (m/z 617.1801 ± 0.001; green; Figure 2c). Overlay of the 57Fe-heme peak (m/z 617.1772 ± 0.001; red) and 56Fe-heme 13C peak (m/z 617.1801 ± 0.001; green) was used to visualize the relative intensity of heme ions, with color gradation from red (derived from newly synthesized heme) to yellow to green (derived from non-labeled heme) in the spleen (Figure 2e). In the same way, overlay of the 57Fe-heme peak (m/z 617.1772 ± 0.001; red) and heme b monoisotopic mass peak (56Fe-heme, m/z 616.1768 ± 0.001; pale blue) was also used to visualize the relative intensity of heme ions, with color gradation from red (derived from newly synthesized heme) to white to pale blue (derived from non-labeled heme) (Figure 2d). There was a Δ1.0004 difference between the 57Fe-heme peak (m/z 617.1772) and the heme b monoisotopic mass peak m/z 616.1768, which was fixed as a lock mass. Comparing the overlay image results in Figure 2d and e, the relative intensities of [57Fe-heme/56Fe-heme] and [57Fe-heme/56Fe -heme 13C] showed exactly the same distribution of gradient patterns in mouse spleens. This result strongly confirms the precision of all acquired data from 37,935 mouse spleen positions with mass resolving power >500,000. The mass accuracies were better than 1.6 ppm between m/z 601.92 and 650.00. Our optimized MALDI FTICR-MSI platform was able to resolve heme M + 1 isotopic fine structure and distinguish the 57Fe-labeled heme peak from the non-labeled 56Fe-heme 13C peak with a Δ0.0029 difference.

Histologic Validation

Following MALDI MSI data acquisition, the DHB matrix was removed from the sample slides by washing with 70% ethanol. The slides were stained with H&E and histologic evaluation was performed to observe the red pulp and white pulp structures of the spleen (Figure 3). In the NT and vehicle-treated mouse spleens, there was an obvious match between the localization pattern of non-labeled heme (56Fe-heme and 56Fe-heme 13C) ion signal intensity from the MSI results and the pattern of red pulp on histology. The areas where 56Fe-heme ion intensities were extremely low in the MSI results corresponded with the white pulp (Figure 3b, c). The data positions #33323/NT, #24722/vehicle, and #9963/C.E.R.A. in Figure 1 were located in red pulp in mouse spleens. In C.E.R.A.-treated mouse spleens, there was a noticeable increase in hematopoietic cells (extramedullary hematopoiesis) (Figure 3a). These results strongly correlated with the localization pattern of 57Fe-heme ion intensity in the MSI results. 57Fe-heme ions were weakly detected in the red pulp area of vehicle-treated mouse spleens (Figure 2b). It is assumed that the stable iron isotope 57Fe from the diet was incorporated into porphyrin in this area. The difference in 57Fe-heme ion intensity between vehicle and C.E.R.A.-treated mice indicates the mode of action of C.E.R.A. and its drug efficacy in mouse spleens.
Figure 3

H&E staining of mouse spleens. Sections of the MS images shown in Figure 2b and c are expanded and compared with the same areas stained with H&E (a), (b), (c). The white pulp (lymphocyte area) is located in areas with extremely low signal in the MS images. The red pulp (erythrocyte area) is located in areas with a strong signal. In C.E.R.A.-treated spleen, increased numbers of erythroblasts are observed (a). Scale bar indicates 250 μm (Figure 3)

H&E staining of mouse spleens. Sections of the MS images shown in Figure 2b and c are expanded and compared with the same areas stained with H&E (a), (b), (c). The white pulp (lymphocyte area) is located in areas with extremely low signal in the MS images. The red pulp (erythrocyte area) is located in areas with a strong signal. In C.E.R.A.-treated spleen, increased numbers of erythroblasts are observed (a). Scale bar indicates 250 μm (Figure 3) In H&E staining images, scars of laser shots (150 shots/pixel) from MALDI MSI data acquisitions were clearly observed (Figure 3). These images displayed evidence that all data were acquired with a precise 50 μm pitch from 37,935 mouse spleen positions, and that the diameter of the laser-pulsed field was less than 50 μm/pixel. These results proved the reliability of the MALDI FTICR-MSI platform in which noise signals from adjacent pixels were minimized.

Conclusions

Our recent study, combining 57Fe-labeling with ICP-MS technology, provided quantitative analysis of dietary iron utilization for hemoglobin synthesis. However, another approach was necessary to analyze detailed tissue iron localization with structural information. In this report, we successfully and completely separated and specifically detected 57Fe-labeled heme isotopic structure from other non-labeled heme peaks using FTICR-MS with ultrahigh resolution power. As a result of effective ionization of heme b and improvement of the lock mass setting, a MALDI FTICR-MSI platform was optimized. The distribution of newly synthesized 57Fe-heme in C.E.R.A.-treated mouse spleens was visualized using the MALDI FTICR-MSI platform. Histologic validation by H&E staining demonstrated the expansion of erythroblasts in C.E.R.A.-treated mouse spleens, confirming the MSI results. These results strongly indicate the effectiveness and reliability of the MALDI FTICR-MSI platform we have optimized. Heme b is a key molecule in vivo, and it is also an indicator of C.E.R.A. drug efficacy. This is the reason why we focused on the heme b isotopes for this investigation. We conclude that the combination of ultrahigh resolution FTICR-MS and stable isotope labeling techniques will be very effective in basic pharmaceutical research. The trend of MALDI MSI is rapid data acquisition to build high resolution 3D images, but on the other hand, MALDI FTICR-MSI platform might be another solution. Below is the link to the electronic supplementary material. (PDF 597 kb)
  23 in total

1.  Matrix sublimation/recrystallization for imaging proteins by mass spectrometry at high spatial resolution.

Authors:  Junhai Yang; Richard M Caprioli
Journal:  Anal Chem       Date:  2011-06-28       Impact factor: 6.986

2.  Petroleomics: the next grand challenge for chemical analysis.

Authors:  Alan G Marshall; Ryan P Rodgers
Journal:  Acc Chem Res       Date:  2004-01       Impact factor: 22.384

3.  A strategy for the determination of the elemental composition by fourier transform ion cyclotron resonance mass spectrometry based on isotopic peak ratios.

Authors:  Daisuke Miura; Yukiko Tsuji; Katsutoshi Takahashi; Hiroyuki Wariishi; Kazunori Saito
Journal:  Anal Chem       Date:  2010-07-01       Impact factor: 6.986

Review 4.  CERA: third-generation erythropoiesis-stimulating agent.

Authors:  Joel Michels Topf
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

Review 5.  Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes.

Authors:  Yuki Sugiura; Mitsutoshi Setou
Journal:  J Neuroimmune Pharmacol       Date:  2009-06-11       Impact factor: 4.147

6.  High resolution mass spectrometry imaging reveals the occurrence of phenylphenalenone-type compounds in red paracytic stomata and red epidermis tissue of Musa acuminata ssp. zebrina cv. 'Rowe Red'.

Authors:  Dirk Hölscher; Jens Fuchser; Katrin Knop; Riya C Menezes; Andreas Buerkert; Aleš Svatoš; Ulrich S Schubert; Bernd Schneider
Journal:  Phytochemistry       Date:  2015-05-21       Impact factor: 4.072

7.  During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool.

Authors:  Arvind Dev; Jing Fang; Pradeep Sathyanarayana; Anamika Pradeep; Christine Emerson; Don M Wojchowski
Journal:  Blood       Date:  2010-09-01       Impact factor: 22.113

8.  A rapid method to assess a broad inventory of organic species in marine sediments using ultra-high resolution mass spectrometry.

Authors:  Jagoš R Radović; Renzo C Silva; Ryan W Snowdon; Melisa Brown; Steve Larter; Thomas B P Oldenburg
Journal:  Rapid Commun Mass Spectrom       Date:  2016-06-15       Impact factor: 2.419

9.  Natural iron isotope variations in human blood.

Authors:  Thomas Walczyk; Friedhelm von Blanckenburg
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

10.  Next-generation technologies for spatial proteomics: Integrating ultra-high speed MALDI-TOF and high mass resolution MALDI FTICR imaging mass spectrometry for protein analysis.

Authors:  Jeffrey M Spraggins; David G Rizzo; Jessica L Moore; Michael J Noto; Eric P Skaar; Richard M Caprioli
Journal:  Proteomics       Date:  2016-05-10       Impact factor: 3.984

View more
  2 in total

Review 1.  Applications of stable isotopes in MALDI imaging: current approaches and an eye on the future.

Authors:  Angus C Grey; Melody Tang; Ali Zahraei; George Guo; Nicholas J Demarais
Journal:  Anal Bioanal Chem       Date:  2021-02-02       Impact factor: 4.142

2.  Nanodelivery vehicles induce remote biochemical changes in vivo.

Authors:  Kristen N Sikora; Laura J Castellanos-García; Joseph M Hardie; Yuanchang Liu; Michelle E Farkas; Vincent M Rotello; Richard W Vachet
Journal:  Nanoscale       Date:  2021-07-15       Impact factor: 8.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.